MedTrace Logo

Feasibility Study of Hematology Parameters in COVID-19 Disease

NCT04816630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2021-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care includes CBC-DIFF and microbial testing.

Conditions

  • Covid19
  • Sepsis
  • Adults
  • Emergency Department

Interventions

DEVICE

CBC-Diff Monocyte Volume Width Distribution

MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.

Sponsors & Collaborators

  • Beckman Coulter, Inc.

    lead INDUSTRY

Principal Investigators

  • Tiffany Osborn, MD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-03-25
Completion
2021-09-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816630 on ClinicalTrials.gov